Clinical

Immune checkpoint inhibitors (ICIs) can increase life expectancy among patients who have non–small cell lung cancer (NSCLC), but they also carry the risk of immune-related adverse events.

Researchers suggest socioeconomic status (SES) be considered in prognostic algorithms going forward.

Adam C. Welch, PharmD, MBA, FAPhA, leads a panel discussion surrounding complications related to RSV infection.

A panel of medical experts discuss the prevalence of RSV in adults.

Budd-Chiari syndrome and myeloproliferative neoplasms (MPNs) are rare, which means available data are limited.

There is a concerted effort to identify biomarkers to understand the risk of progression of diabetic eye disease, but many studies have not been performed in diverse populations, explained Jennifer K. Sun, MD, MPH, associate professor of ophthalmology and chief of the Center for Clinical Eye Research and Trials, Harvard Medical School; and chair, DRCR Retina Network.

Dr Butrus leads a discussion on the ideal patient population for treating atopic dermatitis with ruxolitinib.

The panelists highlight the treatment nature of ruxolitinib, a JAK inhibitor used to treat atopic dermatitis.

Using a diverse human gut community, researchers investigated how gut microbiota interspecies interactions affected the response of Clostridioides difficile to vancomycin and metronidazole.

The training did not, however, affect postoperative limb skeletal muscle weakness or exercise capacity.

Researchers compared chimeric antigen receptor T-cell therapies axicabtagene ciloleucel (axi-cel) and tisagenlecleucel.

Patients who have extrinsic (EAD) or intrinsic atopic dermatitis (IAD) serve to benefit equally from dupilumab, even when considering immunoglobulin E levels, which are elevated in EAD but remain normal in IAD.

Medical experts provide insights surrounding efforts to ensure equitable health for women across underserved patient populations.

Derek van Amerongen, MD, MS, leads a panel discussion surrounding disparities currently facing women in health care.

Findings show these drugs were linked with a lower risk of progression to inflammatory arthritis compared with tumor necrosis factor inhibitors, although more research is needed to confirm the finding.

Dr Matous leads a conversation regarding CAR T-cell therapy for treating multiple myeloma.

The panel provides an overview of drug treatment options for patients with RRMM.

No benefit was found in low-risk patients who underwent pelvic lymph node dissection (PLND).

The findings support policies urging vaccination of individuals who have myasthenia gravis (MG).

The prevalence of Clostridioides difficile has risen in recent years, and although its carriage is recognized in infancy, limited data exist on its longitudinal trends.

An analysis of the EMPOWER‐Lung 3 trial found that the addition of cemiplimab to platinum chemotherapy for non­–small cell lung cancer (NSCLC) was associated with improved patient quality of life (QOL) vs chemotherapy alone.

In addition to current available risk scores, the new system can help counsel patients with myelofibrosis (MF) undergoing allogeneic hematopoietic stem cell transplantation (allo-HCT), authors wrote.

Study authors said the findings could inform clinicians when selecting therapies for patients with type 2 diabetes (T2D). However, an editorial found the follow-up period too short and differences between the study arms too small to be meaningful.

Managing itch associated with atopic dermatitis is a critical intervention to patient quality of life.

Medical experts navigate the selection process for optimal atopic dermatitis treatment strategies from provider and payer perspectives.

To address the research gap in familial focal epilepsy with variable foci (FFEVF), investigators assessed the clinical features of a family with FFEVF that included 4 patients in 3 generations and 1 healthy member.

Fecal microbiota transplantation (FMT) has emerged as a highly successful therapeutic strategy for recurrent Clostridioides difficile infection (CDI) in recent years.

For Brain Cancer Awareness Month, AJMC shares an interview with Day One Biopharmaceuticals CEO Jeremy Bender, PhD, MBA. Bender discussed the company's lead agent, tovorafenib, which has shown promise in treatment of pediatric low-grade glioma.

Jeffrey E. Lancet, MD, chair of the Department of Malignant Hematology at Moffitt Cancer Center, discussed the issue of cost and optimizing patient outcomes acute myeloid leukemia (AML).

A recent study found that patients with advanced solid cancers with high tumor mutational burden (TMB) saw improved outcomes on immune checkpoint inhibitors (ICIs) compared with patients who had low-TMB cancers.